Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corp (NQ: SRRK )

5.490 +0.070 (+1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 824,128
Open 5.290
Bid (Size) 5.150 (1)
Ask (Size) 5.720 (2)
Prev. Close 5.420
Today's Range 5.010 - 5.490
52wk Range 4.325 - 44.95
Shares Outstanding 35,301,654
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga

Performance

YTD
-77.76%
-77.76%
1 Month
+9.36%
+9.36%
3 Month
-57.41%
-57.41%
6 Month
-78.93%
-78.93%
1 Year
-81.00%
-81.00%

More News

Read More
Where Scholar Rock Holding Stands With Analysts
Via Benzinga
Why Scholar Rock Shares Are Trading Higher Today
Via Benzinga
Scholar Rock Shares Jumps On Updating Strategic Priorities
Via Benzinga
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Via Benzinga
67 Biggest Movers From Yesterday
Via Benzinga
Dow Jones Turns Lower; Revlon Shares Jump
Via Benzinga
89 Biggest Movers From Friday
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Via Benzinga
U.S. Markets Open Higher; Dow Rises Around 200 Points
Via Benzinga
Scholar Rock Announces $205 Million Registered Direct Offering
From Scholar Rock
Via Business Wire
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
From Scholar Rock
Via Business Wire
79 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
From Scholar Rock
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
What 4 Analyst Ratings Have To Say About Scholar Rock Holding
Via Benzinga
81 Biggest Movers From Yesterday
Via Benzinga
Mid-Day Market Update: Nasdaq Jumps 200 Points; AutoWeb Shares Slide
Via Benzinga
48 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.